High-throughput screening of PLGA thin films utilizing hydrophobic fluorescent dyes for hydrophobic drug compounds

Steele, Terry W. J.; Huang, Charlotte L.; Kumar, Saranya; Widjaja, Effendi; Boey, Freddy Yin Chiang; Loo, Say Chye Joachim; Venkatraman, Subbu S.

doi:10.1002/jps.22625

Cited by 27 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to interactions between the hydrophobic ends of the dye and alginate solution during emulsification and centrifugation. The use of hydrophobic fluorescent dyes coated in thin PLGA films in formulating hydrophobic drug compounds has been reported (Steele et al,2011). The authors showed that all fluorescent dyes successfully encapsulated in PLGA and released at desirable rates.…”

Section: Discussionmentioning

confidence: 99%

Preliminary studies on pharmaceutical microencapsulation for synbiotic application

Evivie

2013

JANS

View full text Add to dashboard Cite

Abstract:The solvent evaporation technique was used in this study to evaluate probiotics microencapsulation in AQOAT/ dichloromethane matrix and cell viability was also measured to assess its potentials in industrial food formulation processes. Cumulative release experiments using water blue dye as a model molecule was also used to evaluate the prebiotic applications. Well-defined spherical AQOAT microcapsules [50.0 ìm ± (24.14)] were formed from 5% AQOAT solution. Cells of Bifidobacterium breve and Lactobacillus plantarum were successfully encapsulated with this technique. However, a 7 log and a 5 log reduction were recorded for B. breve and L. plantarum respectively after 60 min in buffer (P<0.05). Results of this study showed that 1% AQOAT solution lowered viability by 1 log and cell exposure to 10 ml dichloromethane resulted in a 3 log reduction, thus confirming bactericidal properties of both polymer and organic solvent. DCM was however shown to have more bactericidal effects on the cells (P<0.001). Cumulative release trials using 0.2% water blue dye solution showed a 40% loss and encapsulation efficiency (EE) of 73.8% (±14.76). It was recommended that viability counts using this technique be further evaluated using other organic solvents (such as ethyl acetate and chloroform) or other synthetic polymers so as to increase its applicability in the food industry.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary studies on pharmaceutical microencapsulation for synbiotic application

Evivie

2013

JANS

View full text Add to dashboard Cite

show abstract

“…In this investigation FDAc was used instead of Paclitaxel (PTX) due to the described similar release behavior [11]. P(LLA-co-CL) samples with FDAc incorporated were produced via a spray coating process and the surfaces for the additional biofunctionalization with VEGF were characterized via contact angle measurements.…”

Section: Immobilization and In Vitro Release Of Fdac And Vegfmentioning

confidence: 99%

“…As model drug for bulk incorporation we used fluorescein diacetate (FDAc) with diffusion and distribution coefficients similar to paclitaxel [11]. To immobilize VEGF we generated functional groups on the polymer surface via an established oxygen plasma procedure which also improves hemocompatibility of PLLA-co-CL [12].…”

Section: Introductionmentioning

confidence: 99%

Mutual influence of incorporated drugs in a dual drug delivery coating for cardiovascular applications

Wulf¹,

Teske²,

Matschegewski³

et al. 2017

Current Directions in Biomedical Engineering

View full text Add to dashboard Cite

For a long-term efficient drug-eluting stent for vascular applications, the development of drug-loaded coating, combining the effective inhibition of smooth muscle cell proliferation while promoting the re-endothelialization, is a promising concept. However the mostly required simultaneous incorporation of drugs can influence decisively the stability, efficacy and release of the respective drug. Therefore, the mutual influence of a dual local drug delivery coatings based on poly(L-lactide-co-ε-caprolactone) (PLLAco-CL) containing vascular endothelial growth factor (VEGF 165 ) coupled to the surface and an embedded drug, such as fluorescein diacetate (FDAc) instead of Paclitaxel (PTX) on the in vitro drug release was investigated. Surprisingly, for the investigated coating the immobilized VEGF loading was enhanced and the release profile was accelerated by FDAc incorporation. Even a manifold increase for the in vitro released amounts of VEGF was detected. In contrast, the immobilization of VEGF seems to have a negligible influence on the in vitro FDAc release profiles.

show abstract

“…Therefore, we developed a spray coating procedure with a high bulk drug incorporation and with minor surface changes for possible further surface modifications. As model drug we used FDAc beside PTX because of the similar diffusion and distribution coefficients like PTX [5]. Furthermore the coatings were investigated with respect to changes in glass transition (T G ) because of the potent impact on drug release.…”

Section: Introductionmentioning

confidence: 99%

Influence of bulk incorporation of FDAc and PTX on polymer properties

Teske¹,

Wulf²,

Arbeiter³

et al. 2017

Current Directions in Biomedical Engineering

View full text Add to dashboard Cite

Abstract:In the last decades PLLA-based copolymers have been among the most attractive polymeric candidates used to fabricate devices for drug delivery and stent applications in the cardiovascular system. PLLA is biocompatible and biodegradable, exhibits a wide range of erosion times and has tunable mechanical properties. Therefore, the influence of drug incorporation on the physicochemical properties of biodegradable PLLA copolymers were examined in this study using Fluorescein diacetate (FDAc) and Paclitaxel (PTX). A percental amount of these drugs (17.5 %) were incorporated into poly(L-lactide-co-glycolide) (P(LLA-co-GA)) and poly(L-lactide-co-ε-caprolactone) (P(LLA-co-CL)) made via spray coating. The polymer surface properties, such as surface morphology and hydrophilicity were also examined and remained rather unchanged for both polymers after drug loadings. Furthermore, also the contact angle changed rather marginally. However, both polymers have already different thermal properties without the drug embedded, especially the glass transition temperature (T G ) is for P(LLA-co-CL) under 37 °C and for P(LLA-co-GA) considerable above with around 66 °C. An rather high increase in T G achieved by addition of FDAc or PTX, crucial influences the drug release profiles for P(LLA-co-CL) in contrast to P(LLA-co-GA). Besides these results preliminarily experiments of additional coupling of other drugs on the polymer surface were performed and we obtained an influence of FDAc or PTX. The drug incorporation and physicochemical characterization data obtained in this study is relevant in optimizing the incorporation or coupling of further drugs on the polymer surface and delivery properties of these potential multi drug delivery coatings.

show abstract

High-throughput screening of PLGA thin films utilizing hydrophobic fluorescent dyes for hydrophobic drug compounds

Cited by 27 publications

References 34 publications

Preliminary studies on pharmaceutical microencapsulation for synbiotic application

Preliminary studies on pharmaceutical microencapsulation for synbiotic application

Mutual influence of incorporated drugs in a dual drug delivery coating for cardiovascular applications

Influence of bulk incorporation of FDAc and PTX on polymer properties

Contact Info

Product

Resources

About